Compare Abeona Therapeutics Inc (ABEO) vs Allbirds Inc (BIRD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Allbirds Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Allbirds Inc trades at $3.41 (market cap $30.69M). The key difference: Abeona Therapeutics Inc is far larger — about 12.2× Allbirds Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BIRD | |
|---|---|---|
Market Cap | $373.32M | $30.69M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $16.99 |
52-Week Low | $4.17 | $2.39 |
Enterprise Value | $228.22M | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BIRD (Smartbird) trades at $3.47, down 9.87% today, amid a complete pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with negative cash flows and widening losses, though revenue decline has slowed. Recent news highlights the strategic rebranding and new CEO appointment, driving volatile price action. Analyst consensus remains cautious with 78.57% hold ratings, reflecting uncertainty around the business transformation.
Outlook is highly speculative given the radical business model shift. The AI pivot offers growth potential but carries execution risks amid persistent losses and negative equity. Investors face significant volatility as the company transitions, with success dependent on securing AI infrastructure contracts and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
